Sentences with phrase «timely reports on»

• Delivers timely reports on completed repair back to department heads as needed.

Many schools and districts also have access to timely reports on the college access and persistence rates of their own graduates through the StudentTracker ® service of the National Student Clearinghouse.

A major requirement was to write clear, succinct, and timely reports on each industrial site's adherence (or lack thereof) to federal regulations, so I quickly learned the challenges of effective writing!

The Institute for Government's timely report on practical challenges facing the final year of coalition government, outlined areas where increasing politicisation will mean channels of information between parties become squeezed and the arteries of government clogged.

(I read about the study in an article from ww.nutraingredients-use.com, a source I love for its accurate, timely reporting on new studies about supplements and good - for - you foods.)

North Olmsted, Ohio About Blog Dermatology Times is a weekly news magazine and leading information source for dermatologists, offering credible, relevant and timely reporting on the latest trends in the speciality.

North Olmsted, Ohio About Blog Dermatology Times is a weekly news magazine and leading information source for dermatologists, offering credible, relevant and timely reporting on the latest trends in the speciality.

Crisp, insightful, timely reporting on issues and events that matter to physical scientists across a broad spectrum.

Prepare a timely report on sales, fiancé and marketing for future reference purpose.

North Olmsted, Ohio About Blog Dermatology Times is a weekly news magazine and leading information source for dermatologists, offering credible, relevant and timely reporting on the latest trends in the speciality.

North Olmsted, Ohio About Blog Dermatology Times is a weekly news magazine and leading information source for dermatologists, offering credible, relevant and timely reporting on the latest trends in the speciality.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Twice a week, the team brings you an entertaining and well - researched report on timely topics relevant to your life, from what's happening with the Brexit to why it takes so long to scan that chip in your credit card.

In the U.S., we generally believe that publicly - held firms are to be managed for «shareholder value» (technically, the Securities Exchange Commission's Code of Ethics for CEOs only requires the firm to provide full, fair, accurate and timely financial reporting, and to flag any known conflicts of interest or violations of securities law, but state laws often impose stricter fiduciary duties on the firm's top managers).

Actual results, including with respect to our targets and prospects, could differ materially due to a number of factors, including the risk that we may not obtain sufficient orders to achieve our targeted revenues; price competition in key markets; the risk that we or our channel partners are not able to develop and expand customer bases and accurately anticipate demand from end customers, which can result in increased inventory and reduced orders as we experience wide fluctuations in supply and demand; the risk that our commercial Lighting Products results will continue to suffer if new issues arise regarding issues related to product quality for this business; the risk that we may experience production difficulties that preclude us from shipping sufficient quantities to meet customer orders or that result in higher production costs and lower margins; our ability to lower costs; the risk that our results will suffer if we are unable to balance fluctuations in customer demand and capacity, including bringing on additional capacity on a timely basis to meet customer demand; the risk that longer manufacturing lead times may cause customers to fulfill their orders with a competitor's products instead; the risk that the economic and political uncertainty caused by the proposed tariffs by the United States on Chinese goods, and any corresponding Chinese tariffs in response, may negatively impact demand for our products; product mix; risks associated with the ramp - up of production of our new products, and our entry into new business channels different from those in which we have historically operated; the risk that customers do not maintain their favorable perception of our brand and products, resulting in lower demand for our products; the risk that our products fail to perform or fail to meet customer requirements or expectations, resulting in significant additional costs, including costs associated with warranty returns or the potential recall of our products; ongoing uncertainty in global economic conditions, infrastructure development or customer demand that could negatively affect product demand, collectability of receivables and other related matters as consumers and businesses may defer purchases or payments, or default on payments; risks resulting from the concentration of our business among few customers, including the risk that customers may reduce or cancel orders or fail to honor purchase commitments; the risk that we are not able to enter into acceptable contractual arrangements with the significant customers of the acquired Infineon RF Power business or otherwise not fully realize anticipated benefits of the transaction; the risk that retail customers may alter promotional pricing, increase promotion of a competitor's products over our products or reduce their inventory levels, all of which could negatively affect product demand; the risk that our investments may experience periods of significant stock price volatility causing us to recognize fair value losses on our investment; the risk posed by managing an increasingly complex supply chain that has the ability to supply a sufficient quantity of raw materials, subsystems and finished products with the required specifications and quality; the risk we may be required to record a significant charge to earnings if our goodwill or amortizable assets become impaired; risks relating to confidential information theft or misuse, including through cyber-attacks or cyber intrusion; our ability to complete development and commercialization of products under development, such as our pipeline of Wolfspeed products, improved LED chips, LED components, and LED lighting products risks related to our multi-year warranty periods for LED lighting products; risks associated with acquisitions, divestitures, joint ventures or investments generally; the rapid development of new technology and competing products that may impair demand or render our products obsolete; the potential lack of customer acceptance for our products; risks associated with ongoing litigation; and other factors discussed in our filings with the Securities and Exchange Commission (SEC), including our report on Form 10 - K for the fiscal year ended June 25, 2017, and subsequent reports filed with the SEC.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

In addition to factors previously disclosed in Tesla's and SolarCity's reports filed with the U.S. Securities and Exchange Commission (the «SEC») and those identified elsewhere in this document, the following factors, among others, could cause actual results to differ materially from forward - looking statements and historical performance: the ability to obtain regulatory approvals and meet other closing conditions to the transaction, including requisite approval by Tesla and SolarCity stockholders, on a timely basis or at all; delay in closing the transaction; the ultimate outcome and results of integrating the operations of Tesla and SolarCity and the ultimate ability to realize synergies and other benefits; business disruption following the transaction; the availability and access, in general, of funds to meet debt obligations and to fund ongoing operations and necessary capital expenditures; and the ability to comply with all covenants in the indentures and credit facilities of Tesla and SolarCity, any violation of which, if not cured in a timely manner, could trigger a default of other obligations under cross-default provisions.

However, your timely payments will likely be reflected on your business credit report the same as any other revolving debt — provided the leasing company reports to the business credit bureaus (which it probably does).

Wells Fargo Investment Institute provides timely reports based on questions many investors have on their minds.

Of particular note is a resolution seeking a report on gender pay equity — timely, given that the U.S. Department of Labor recently accused the company of «systematic compensation disparities against women.»

«Debtwire is an invaluable resource that provides timely reporting and enables me to not only keep up on news regarding my clients but also generate new business leads.»

Now that Victoria and Queensland have reported on their inquiries into the greyhound racing industry, it is timely to consider the findings of the reports and their implications for the animal industries of Australia.

Check out the SportsInsights.com Blog for timely betting trends reports, plus original analysis on featured games and strategies.

What is also of grave concern to AIMS Ireland is the number of failures at national level identified in the report including timely access to maternity services, inadequate staffing levels for safe care, a maternity care model that hasn't been revised in 59 years despite numerous national and international reports and recommendations, a lack of accountability and governance, an absence of reviews of clinical practices in units and the lack of a national maternity services strategy, all of which we have seen recommended on previous inquests without reform.

As required by section 706 of the Telecommunications Act of 1996, as amended, we issue this Report on our annual inquiry regarding the availability of «advanced telecommunications capability» to all Americans and to determine whether such capability is being deployed to all Americans in a reasonable and timely fashion.

But this relies on timely reporting.

A report by the London Assembly found that initial health screenings that occur on arrival are not effective at flagging up mental health problems, and since staff lack access to GP records, opportunities to provide the correct and timely support are lost.

Bill Hammond: «As Albany lawmakers consider imposing costly new taxes and mandates on health insurance, a report from the New York State Health Foundation offers a timely reminder: The state's premiums are already among the highest in the country, and rising fast.»

As Albany lawmakers consider imposing costly new taxes and mandates on health insurance, a report from the New York State Health Foundation offers a timely reminder: The state's premiums are already among the highest in the country, and rising fast.

Rather than concentrating on improving the current system and insuring the timely designations and re-authorizations of state certified MWBE companies and their entry into the universe of state contracting, the law increases the arbitrary power of the director of the program while complicating the reporting systems required of contractors.

«By placing a law on the books requiring parents and guardians to report missing children who are in significant danger in a timely manner, we will ensure for the future that parents are going to be held accountable for their actions.

The report refers to a «timely» budget or one that was approved «essentially on time» that reflects a significant improvement in the state's fiscal picture since the end of the economic recession.

On more than 12 occasions, Suffolk County probation officers failed to alert prosecutors in a timely manner that convicted drunken drivers attempted to drive while under the influence or tampered with court - ordered ignition interlock devices, according to a report by the state comptroller's office.

The report draws on government and trade statistics, academic evidence and economic theory to challenge arguments that the health and social benefits of reducing alcohol consumption are likely to come at a cost to the economy, finding: · Any reduction in employment and income resulting from lower spending on alcohol would be offset by spending on other goods · Econometric analysis of US states suggests that a 10 % decrease in alcohol consumption is associated with a 0.4 % increase in per capita income growth · Lower alcohol consumption could also reduce the economic costs of impaired workplace productivity, alcohol - related sickness, unemployment and premature death, which are estimated to cost the UK # 8 - 11 billion a year The analysis comes at a timely moment, with health groups urging the Chancellor to raise alcohol duty in next month's Budget.

This is a subject both intensely timely and well suited to Alessandra's skills as an observer, reporter and writer... she'll be reporting on what she describes as the «psychology, rituals, costs and contradictions» of a new generation of American titans.»

Burstein continued: «Our reports are available on our website within approximately two weeks of the inspectors» actual onsite visit, providing the timeliest access to this information.

While Chief Fowler refused to report to the CRB on his responses to its disciplinary recommendations in cases it took the CRB more than six months to investigate, Mayor Miner vetoed $ 15,000 for part - time consultants to help the CRB resolve complicated cases in timely fashion.

The Governor did touch on the current controversy surrounding the Department of Child Services, he did not go into much detail, however, he did say he would be transparent about the agency's review process and promise timely progress reports.

With union militancy growing Mr Maude and his ministerial colleagues would be wise to examine a timely report from Policy Exchange on «modernising industrial relations».

«I have been notified by the SEC that, in connection with a board appointment I received, certain stock grants given me were not timely reported to the SEC,» Paterson declared, according to a brief note on his record.

I followed up with a piece a couple of years ago for The News, reporting on Smith's failure to file timely reports once he moved to the Council.

Bills are pending in the Legislature toward that end — to require court - ordered attorney fees when agencies wrongly deny information; to allow judges to order officials to undergo training and report their FOIL compliance to the state Committee on Open Government; and to require them to file timely appeals — within 30 days — in cases like Cuomo v. Robinson.

This work is particularly timely given the work this year of the Intergovernmental Panel on Climate Change (IPCC) to develop a Special Report on the Impacts of global warming of 1.5 oC above pre-industrial levels.

«It is stunning that we in the United States must turn to a UK newspaper website for timely and detailed reporting on deaths due to police violence,» the authors write.

The Health Reform Monitoring Survey (HRMS)- Texas report is based on the HRMS, a national project that provides timely information on implementation issues under the Affordable Care Act (ACA) and changes in health insurance coverage and related health outcomes.

David Pollard: «Every student has a right to expect a timely response on a draft of a report, thesis chapter, or manuscript.

«Our use of an electronic medical record - generated daily report, with additional information on the rationale behind each prescription event was somewhat novel and incredibly useful in providing timely feedback and review of prescriber practices.»

The WebMD Diet Guide is your ally on your journey to healthy eating --- with timely, credible healthy eating and weight loss information; unbiased reports on diet plans from A to Z; personalized tools for counting calories, assessing your diet, and evaluating portion sizes; and much more.

As in the past, this year's edition is built on twin foundations: the detailed data collection and analysis of the Editorial Projects in Education Research Center, which mines its annual policy survey to provide comprehensive, state - by - state grading in key areas of state policy and performance; and the rigorous investigation of a timely issue in education policy by the Education Week reporting staff.